Navega is developing epigenetic regulation gene therapies via CRISPR-dCas9 (nuclease null), and zinc fingers, for neurological disorders. Our first indication is a rare disease-Erythromelalgia-in which patients have chronic pain due to a gain-of-function mutation in Nav1.7. This same gene therapy could also be utilized for other chronic pain indications (neuropathic pain, low back pain, etc). We are expanding our pipeline to other neurological indications, including epilepsy.
LifeSci
Navega Therapeutics
OTHER COMPANIES
